Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by David R. D’Adamo
Eribulin Versus Dacarbazine in Patients With Leiomyosarcoma: Subgroup Analysis From a Phase 3, Open-Label, Randomised Study
British Journal of Cancer
Cancer Research
Oncology
Related publications
Efficacy and Safety of Trabectedin or Dacarbazine for the Treatment of Patients With Uterine Leiomyosarcoma After Prior Chemotherapy: A Subgroup Analysis of the Randomized Phase 3 SAR-3007 Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine
British Journal of Cancer
Cancer Research
Oncology
Ibrutinib Versus Temsirolimus: 3-Year Follow-Up of Patients With Previously Treated Mantle Cell Lymphoma From the Phase 3, International, Randomized, Open-Label RAY Study
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Response-Adapted Intensification With Cyclophosphamide, Bortezomib, and Dexamethasone Versus No Intensification in Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial
The Lancet Haematology
Hematology
Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial
The Lancet Oncology
Oncology
A Randomised, Open-Label, Crossover Study of the Dopamine Agonist, Pramipexole, in Patients With Sleep Bruxism
Journal of Sleep Research
Medicine
Behavioral Neuroscience
Cognitive Neuroscience
Infliximab for Pediatric Patients With Ulcerative Colitis: A Phase 3, Open-Label, Uncontrolled, Multicenter Trial in Japan
BMC Pediatrics
Child Health
Pediatrics
Perinatology
Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine as a Preparative Regimen for Allogeneic Haemopoietic Stem-Cell Transplantation in Patients With Acute Myeloid Leukaemia: An Open-Label, Multicentre, Randomised, Phase 3 Trial
The Lancet Oncology
Oncology
A Multi-National, Randomised, Open-Label, Parallel, Phase III Non-Inferiority Study Comparing NK105 and Paclitaxel in Metastatic or Recurrent Breast Cancer Patients
British Journal of Cancer
Cancer Research
Oncology
